ID 120040002
Alternative Names: ID-120040002Latest Information Update: 19 Mar 2025
At a glance
- Originator Ildong Pharmaceutical
- Class Antiulcers; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastro-oesophageal reflux
Most Recent Events
- 19 Mar 2025 Phase-II clinical trials in Gastro-oesophageal reflux in South Korea (unspecified route) Prior to March 2025 (Yuvonia Pipeline, March 2025)
- 07 Dec 2022 Phase-I clinical trials in Gastrointestinal disorders (In volunteers) in South Korea (unspecified route) (NCT05663879)
- 03 Jan 2022 Ildong Pharmaceutical announces intention to submit IND application for Gastrointestinal disorders (Ildong pharmaceutical pipeline,